1. You Are At:
  2. English News
  3. India
  4. Haryana stops production of cough syrups at Sonipat's Maiden Pharma linked to deaths in Gambia

Haryana stops production of cough syrups at Sonipat's Maiden Pharma linked to deaths in Gambia

Haryana: The report for the samples of three drugs of the Sonipat-based pharmaceutical company, which were mentioned by the WHO, are yet to come, state Health Minister Anil Vij said.

Vani Mehrotra Edited By: Vani Mehrotra @vani_mehrotra New Delhi Updated on: October 12, 2022 13:28 IST
Maiden Pharma, Maiden Pharma cough syrup, Haryana,
Image Source : PIXABAY Haryana government halts all productions from Maiden Pharma cough syrup plant

Highlights

  • Maiden Pharmaceuticals was recently flagged by WHO in concern of deaths in The Gambia
  • The company has also been issued a show cause notice
  • WHO said it was conducting investigation with the company and regulatory authorities in India

The Haryana government has ordered to completely halt the production of cough syrups at Sonipat-based company Maiden Pharmaceuticals Limited. The development comes after the company was recently flagged by the World Health Organisation (WHO), in wake of the deaths of 66 children in The Gambia. 

The company has also been issued a show cause notice for 12 violations found at its manufacturing plant.

Commenting on the development, state health minister Anil Vij on Wednesday said, "The samples of three drugs of the Sonipat-based pharmaceutical company which were mentioned by WHO, have been sent to Central Drug Laboratory in Kolkata. The report is yet to come."

"We will take action only after the report comes. After a joint inspection by Central and State officials, 12 violations were found in the manufacturing facility. It has been decided to shut down total production. We have sent a notice in this regard," Vij added.

Concerns against cough syrups manufactured by Maiden Pharmaceuticals

The pharma company had come under scanner following the death of 66 children who had consumed the cough syrup in The Gambia.

The WHO, on October 5 issued a medical product alert over four India-made cough and cold syrups manufactured by Maiden Pharmaceuticals. 

WHO has also notified that the same cough and cold syrups could be linked to the deaths of 66 children in The Gambia.

It said that it was conducting further investigation with the company and regulatory authorities in India. 

"This WHO Medical Product Alert refers to four substandard products, identified in The Gambia and reported to WHO in September 2022. Substandard medical products are products that fail to meet either their quality standards or specifications and are, therefore "out of specification," the WHO said.

According to the WHO, the four cough syrups linked to the deaths in The Gambia are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup.

Laboratory analysis of samples of each of the four products confirmed that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants, the WHO had said.

The company was issued a show cause notice on October 7 after a joint inspection with the Central Drugs Standard Control Organisation. 

The pharma company has to reply to the notice by October 14, failing which action may be taken against it.

Contraventions during inspections of company's facility

The Haryana drug controller has listed the contraventions detected during inspections of the pharma company's facility on October 1 and October 3. 

They include that complete plant found under renovation. 

The firm failed to produce the log books of equipment and instruments regarding manufacturing and testing for the drugs in question.

It said the batch number of propylene glycol, sorbitol solution and sodium methyl paraben used in the manufacturing of the drugs in question were not mentioned in the certificate of the analysis report.

"The firm has not performed process validation and analytical method validation for the drug products in question," it said in the notice. The firm has submitted six month real-time and accelerated stability data of drugs in question. However, at the time of investigation, none of above-said products were found to be charged in the stability chamber," the state drug controller said in the notice.

The notice to the pharma company stated that manufacturing and expiry dates were missing on the certificate of analysis of certain batches of propylene glycol. 

"Propylene glycol (batch number E1007/UP, E1105149) had failed as per certificate of analysis for the test in respect of water but was declared as of standard quality," the notice added.

Also, batch numbers, manufacturer name, and manufacturing and expiry dates were not found on purchase invoices of items used, including propylene glycol.

The firm has also not performed the quality testing of Propylene Glycol for Diethylene Glycol and Ethylene Glycol, the notice said.

The show cause notice to the pharma company has been served under "Rule 85(2) of Drug Rules, 1945 as to why your manufacturing license may not be suspended/cancelled. Your reply to this show cause notice must reach this office within 7 days of the receipt of this notice, failing which ex-parte action shall be liable to be taken against you as per the Drugs and Cosmetics Act, 1940 & Rules, 1945."

Maiden Pharmaceuticals' response 

Meanwhile, reacting to the allegations, Maiden Pharmaceuticals on October 8 said, "We are shocked to hear the media reports regarding the deaths and deeply saddened on this incident but we received the official information from our agent at The Gambia on October 5, 2022, and on the subsequent date, World Health Organisation alert was issued against us."

In an official statement the company's Director, Vivek Goyal said, "We are in the field of medicines for over three decades and have been diligently following the protocols of the health authorities including Drugs Controller General (India) and the State Drugs Controllers, Haryana."

He further said that they have valid drug approvals for the export of the products and his company is not selling anything in the domestic market. He also added that his company is obtaining raw materials from certified and reputed companies.

"The government agencies visited our factory on October 1 and October 3, October 6 and 7 October and the samples were drawn by the Central Drugs Standard Control Organisation (CDSCO) along with all relevant documents in question in presence of our directors," Goyal said in the statement.

The drug regulators had collected the samples of cold and cough syrup from the manufacturing facility of Maiden Pharmaceuticals, after WHO issued a medical alert.

"The samples have been drawn by the CDSCO officials and we are awaiting the results and since the matter is already pending investigation and subjudice, we cannot comment on any other issues and shall update you in the future as and when we receive the information," he added. 

(With inputs from ANI)

Also Read | Govt asks WHO to share report on child deaths in Gambia linked with India-made cough syrups

Latest India News

Read all the Breaking News Live on indiatvnews.com and Get Latest English News & Updates from India